EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Jack Talley has resigned as President and CEO of the Company and as a member of the Board of Directors effective August 20, 2012.
Alan W. Dunton, MD, Non-Executive Chairman of the Board of EpiCept, commented, "Mr. Talley joined EpiCept as President and CEO in October 2001. He was instrumental in the approval of Ceplene in the EU and obtaining a partnership for its launch. We wish Jack the best in his future endeavors."
EpiCept's Board of Directors also announced today that Robert Cook has been appointed interim President and CEO of EpiCept. Mr. Cook has been the Chief Financial Officer of EpiCept since joining the Company in April 2004.
EpiCept engaged SunTrust Robinson Humphrey in January 2012 to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™ for the treatment of CIPN following taxane-based therapy. The engagement is focused on the identification and implementation of a strategy designed to optimize AmiKet™'s value for the Company's stockholders, which includes the evaluation of potential transactions involving the sale of the Company.